Kymera Therapeutics (NASDAQ: KYMR) reported Q1 EPS of ($0.82), $0.07 better than the analyst estimate of ($0.89). Revenue for the quarter came in at $22.1 million versus the consensus estimate of $11.38 million.

For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.